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the molecular basis of the human anti-GBM autoantibody re-Human antiglomerular basement membrane autoantibody dis-
sponse and the opportunity to test specific therapies aimed atease in XenoMouse II.
modulation of either B cells producing human autoantibodiesBackground. Previous studies have identified regions within
or the human pathogenic antibodies themselves, in vivo, prior3(IV) collagen in human antiglomerular basement membrane
to trial in patients with the spontaneous form of the disease.(anti-GBM) disease, however, information pertaining to the
nature of the pathogenic human autoantibodies has been lim-
ited by a lack of a relevant disease model. Availability of
engineered mice that produce antibodies (that is, XenoMouse
Antiglomerular basement membrane (anti-GBM) dis-II strains) provides an ideal opportunity to examine the hu-
ease is a human autoimmune disease mediated by theman antibody response.
Methods. XenoMouse II mice that produce human IgG2 spontaneous production of antibodies against 3(IV)
(2) in response to antigenic challenge were immunized with collagen [1, 2]. Spontaneously produced anti-GBM anti-
various forms of 3(IV)NC1 GBM collagen, including native bodies often cause linear deposits of IgG within thebovine 3(IV) NCl collagen, E. coli expressed r 3(IV)NCl,
GBM that initiate rapidly progressive glomerulonephri-and mammalian fetal kidney 293 cell expressed r 3(IV)NC1
tis. When the autoantibodies bind to exposed epitopespreparations. The mice were evaluated for autoantibody (Ab)
production and nephritis. within the lung, they initiate inflammation and hemor-
Results. All immunized XenoMouse II animals produced rhage, and this pulmonary-renal syndrome is referred to
human anti-GBM Ab associated with proliferative glomerulo- as Goodpasture’s syndrome [3]. Evidence for the patho-nephritis, linear IgG deposits along the murine GBM and tubu-
genicity of the autoantibodies is derived from passivelar basement membrane (TBM), C3 deposits (weaker). A fully
transfer studies, where administration of human anti-human mAb (Ig 2), produced from a mouse immunized with
native bovine 3(IV)NCl collagen produced basement mem- GBM antibodies bound to the GBM and caused immedi-
brane deposits, nephritis and proteinuria on transfer to normal ate glomerulonephritis in monkeys [4]. Furthermore,
XenoMouse II. Furthermore, monoclonal antibodies (mAb) heterologous or homologous crude GBM preparationsshared idiotypic properties with polyclonal autoantibodies de-
induced severe glomerulonephritis with linear IgG andrived from patients with anti-GBM disease, supporting a struc-
C3 deposition on the GBM [5].tural relationship among the antibodies.
Conclusions. The results further support the importance of Subsequent identification and isolation of 3(IV) col-
3(IV)NCl collagen in the pathogenesis of anti-GBM disease. lagen as the principal target of the human autoantibody
Moreover, to our knowledge this is the first demonstration
response has provided the unique opportunity to studythat experimentally induced, pathogenic human autoantibodies
more precisely both this antigen and its major antigenicresult in disease. This new model of anti-GBM disease, there-
fore, provides the means and unique reagents to both decipher epitopes [6–11]. Most of the pathogenic antibodies de-
rived from serum and kidney eluates of patients react
with this protein [12]. The human autoantibody response
1 See Editorial by Borza and Hudson, p. 1905. is characterized by high affinity Ab targeted at a re-
stricted number of epitopes of the non-collagenous do-Key words: anti-GBM disease, human autoantibody, XenoMouse II,
animal model, mouse model, B cell, progressive glomerulonephritis. main of 3(IV) collagen [13, 14]. Furthermore, following
immunization of normal mice with 3(IV) collagen, theReceived for publication August 30, 2001
animals develop disease that resembles the human formand in revised form December 10, 2001
Accepted for publication December 12, 2001 of the disease [15].
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molecular basis of the pathogenic human autoimmune Blood, kidney and lung tissues were collected from
the mice at the time of sacrifice, and the tissues wereresponse has been limited by lack of access to individual
pathogenic antibodies and the disease-relevant immune either immediately snap-frozen in isopentane or fixed in
10% phosphate saline-buffered formalin. The lungs werecells that produce them. To address this problem, we
utilized a unique genetically engineered murine strain expanded with OTC [1:1 dilution with phosphate-buf-
fered saline (PBS)] prior to their removal. At sacrifice,termed XenoMouse II that produces only human immu-
noglobulins [16, 17]. Of particular relevance, B cells from serum samples were obtained for determination of serum
creatinine concentrations (Sigma Chemical Co., St. Louis,this strain undergo IgM to IgG isotype switching after
appropriate stimulation [17]. Following immunization with MO, USA) and3(IV)NC1 antibody levels. For histologic
analysis tissue fixed in 10% buffered formalin was sec-various 3(IV) collagen preparations, including either
bovine 3(IV)NC1 dimers or Escherichia coli expressed tioned, stained with both hematoxylin and eosin (H&E)
or periodic acid Schiff (PAS) and visualized by lightrecombinant 3(IV)NC1 collagen, the mice develop cir-
culating human anti-GBM antibodies, glomerular IgG de- microscopy. The sections were coded and viewed in a
single blinded fashion. All sections were viewed in atposits and glomerulonephritis. A monoclonal autoanti-
body, derived from an animal immunized with bovine least 10 fields without the examiners knowing the iden-
tity of the mouse. Frozen tissues were cryostat-sectioned3(IV)NC1 collagen produced nephritis on passive
transfer. (4 ) and stained with either FITC-conjugated goat anti-
human IgG (Southern Biotechnology Associates, Inc.,
Birmingham, AL, USA), or goat anti-mouse C3 (Sigma
METHODS
Chemical Co.), as described [15].
Preparation of 3 collagen antigens
Determination of anti-3(IV)NC1 antibody activityBovine 3(IV)NC1 dimers were isolated from bovine
testis after digestion with bacterial collagenase, gel fil- A previously described method was used [2]. Briefly,
Immulon II plates were coated with 200 ng of either re-tration and reverse-phase high-pressure liquid chroma-
tography (HPLC) using previously described methods combinant 3(IV)NC1 antigen or 100 ng of 3(IV)NC1
bovine collagen as previously described [12]. The titers[2, 6]. Recombinant 3(IV)NC1 antigen was prepared as
described [18, 19]. Eucaryotic recombinant 3(IV)NC1 of human anti-3(IV)NC1 collagen antibody (Ab) in
serum were then assayed by enzyme-linked immunosor-was expressed in human fetal 293 kidney cells [20]. The
purity of the preparations was determined using anti- bent assay (ELISA) [19].
3(IV) collagen chain-specific antibodies by ELISA and
Hybridoma and monoclonal antibody productionWestern blot prior to use, as described [15].
Immediately after sacrifice (day 28), single cell sus-
Induction/analysis of anti-GBM disease pensions of XenoMouse II spleens were fused to the my-
eloma fusion partner Sp2 mIL6, as previously describedGenetically engineered XenoMouse II strains were
produced as previously described [17]. XenoMouse II [21]. ELISA was used to test supernatants from individ-
ual wells containing hybridomas for anti-3(IV)NC1 anti-animals were immunized with 25 g of 3(IV)NC1 anti-
gen preparations (detailed later in this article) subcuta- body activity. Positive wells were passed into 24 well
plates, sub-cloned twice and screened/selected for binders.neously in complete Freund’s adjuvant (CFA), followed
by a 25-g subcutaneous soluble booster injection two
Determination of species of origin of the mAbto three weeks later [17]. A soluble boost of antigen (25
g) was given subcutaneously four days prior to sacrifice. The following assays were performed in order to un-
equivocally show that the heavy chain was not of murineControl XenoMouse II animals were injected with either
CFA (2 animals) or with normal human IgG in CFA (2 origin and that the light chain was human kappa (as there
can be leak of mouse lambda). For the mouse gammaanimals) and then were boosted with phosphate buffered
saline on the schedule described above. An additional chain assay, Immulon II plates were coated overnight at
4C with 500 ng of sheep anti-mouse IgG in borate buffer.four control mice were immunized with 293 cell ex-
pressed human 1(IV)NC1 collagen as detailed above The plates were then blocked with 1% bovine serum albu-
min (BSA). Undiluted supernatant from either Xeno-for 3(IV)NC1 collagen.
For evaluation of proteinuria mice were placed for 24 Mouse II derived monoclonal antibody (mAb) F1.1, an
irrelevant mouse IgG mAb, or anti-GBM human serumhours in metabolic cages immediately prior to sacrifice.
Proteinuria was measured using a BCA protein assay (1:500) was added for one hour at 37C. After washing,
goat anti-mouse alkaline-phosphatase conjugated IgG, di-according to the manufacturer’s instructions (Pierce,
Rockford, IL, USA). Specimens were tested in duplicate luted 1/2000, was added for one hour at 37C, and the
plates were then developed as described [19].and measured against a standard curve. The specimens
were diluted to fit the linear part of the standard curve. For the human kappa chain assay Immulon II plates
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(Dynex Technologies, Chantilly, VA, USA) were coated hour at 37C. The mixtures were then transferred into
Immulon II wells and incubated for an additional onewith 200 ng of E. coli expressed recombinant 3(IV)NC1
antigen as previously described [19]. After blocking the and a half hours at 37C. After addition of alkaline phos-
phatase-conjugated goat anti-rabbit antibody (1:1000)plates with 1% BSA, supernatant from XenoMouse II
derived mAb F1.1 was added for one hour at 37C. Bio- that had been pre-adsorbed against human IgG the wells
were incubated for an additional hour at 37C. The wellstinylated goat anti-human kappa antibody was added for
one hour at 37C. After washing, streptavidin conjugated were then washed, developed and read at wavelength
405 nm.to alkaline phosphatase was diluted 1/1000, and was
added for one hour at 37C. The plates were then devel-
Passive transfer experimentsoped as described [19].
Four Xenomouse II mice were intravenously adminis-
ELISA binding of mAb F1.1 to 3(IV)NC1 tered 5 mg of purified mAb F1.1, four more were injected
intravenously with 5 mg affinity-purified patient poly-Immulon II plates (Dynex Technologies) were coated
with 200 ng of either E. coli expressed recombinant clonal anti-GBM autoantibody, and a further four con-
trol mice were injected intravenously with 5 mg normal3(IV)NC1 antigen or 200 ng of human 293 fetal kidney
cell expressed antigen in coating buffer. After blocking human IgG. Five days after autoantibody injection,
quantitation of proteinuria was performed, the mice(1% BSA/PBS) and washing, monoclonal or polyclonal
anti-3(IV)NC1 antibody preparations were added to were sacrificed, and the kidneys were evaluated histolog-
ically as described above.the plates and incubated for one hour at 37C. The plates
were then washed and further incubated with 1:1000
Direct immunofluorescence of XenoMouse II kidneysalkaline phosphatase conjugated goat anti-human IgG
for one hour at 37C. The plates were then developed Mouse kidney tissue was frozen in OCT and sectioned
to 4 m. After fixing the tissue to positively chargedwith p-nitrophenyl phosphate (Sigma Chemical Co.) and
read after 30 minutes at wavelength 405 nm. slides (Fisher Scientific, Newark, DE, USA) the slides
were washed three times with PBS, fixed for 10 minutes
Western blot analysis of mAb F1.1 to 3(IV)NC1 with ether/ethanol, and for 20 minutes with 95% ethanol.
They were then rewashed three times in PBS and incu-Western blot analysis was done using a modified
Lamely technique. A 12% sodium dodecyl sulfate-poly- bated with FITC-conjugated goat anti-human IgG. After
a final wash step the slides were mounted (Aquamount;acrylamide gel electrophoresis (SDS-PAGE) running gel
and 4% stacking gel were loaded with either 3 g of Fisher Scientific) and treated with anti-fade (Biorad,
Hercules, CA, USA). The slides were dried at 4C andrecombinant E. coli expressed 3(IV)NC1 antigen or 5
g of recombinant human 3(IV)NC1 expressed by 293 viewed and imaged the following day.
fetal kidney cells. After transfer the Immobilon P mem-
Binding of monoclonal anti-3(IV) NC1 autoantibodybranes were blocked with 5% carnation milk/TBS Tween
to normal human kidney0.05% (TBST) and incubated for an hour at 37C with
monoclonal or polyclonal antibody preparations [poly- Normal human kidney tissue was frozen in OCT and
sectioned to 4 m. After fixing the tissue to positivelyclonal human sera were diluted 1:2000 (RP , JG )]
and neat supernatants. The membrane lanes were then charged slides (Fisher Scientific) they were washed three
times with PBS, fixed for 10 minutes with ether/ethanol,washed (1 with TBST, 1 with 0.05% NP40, 2 with
TBST) and incubated for an hour at 37C with 1:2000 and for 20 minutes with 95% ethanol. After rewashing
with PBS the tissue was incubated with polyclonal anti-horseradish peroxidase-conjugated goat anti-human IgG.
The membrane lanes were then rewashed and developed GBM serum or mAb F1.1 supernatant (20 mg/mL) di-
luted 1:50 for one hour. The tissue was then rewashedusing the Enhanced Chemiluminescent System (ECS)
according to the manufacturer’s instructions (Amer- and incubated with FITC-conjugated goat anti-human
IgG. After a final wash the tissue was mounted (Aqua-sham, Buckinghamshire, UK).
mount, Fisher Scientific) and treated with anti-fade (Bio-
Evaluation of Id-GBM activity rad). The slides were dried at 4C and viewed and imaged
the following day.Competitive inhibition assays were performed as pre-
viously described [19]. Briefly, Immulon II wells were
coated with 0.5 g of recombinant 3(IV) NC1 affinity
RESULTS
purified patient anti-GBM autoantibodies. Rabbit anti-
XenoMouse II strains develop proliferative GNId serum (dilution predetermined by a direct binding
mediated by human anti-GBM antibodiestitration assay) was then diluted in 3% BSA/PBS and
pre-incubated with serial dilutions of XenoMouse II- XenoMouse II animals developed human anti-GBM
antibodies in serum following immunization with eachderived monoclonal antibody (Id) supernatant for one
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Table 1. Anti-glomerular basement membrane (GBM) nephritis in XenoMouse II
Antigen (N) Prea Postb Pr mg/24 h SCr mg/dL Proliferative GN Linear IF
Control (4) 0.06 0.06 	1.0 0.07
0.03 — —
E. coli (4) 0.09 2.8 2.4 0.4  
Bovine (4) 0.14 0.62d 2.8 1.03  
293 Fetal kidney (4) 0.14 2.3 1.6 1.1  
Abbreviations are: Pr, proteinuria; SCr, serum creatinine; GN, glomerulonephritis; IF, immunofluorescence.
a Average serum (1:100) anti-GBM antibody binding at OD 405 after the initial immunization with antigen (ELISA)
b Average serum (1:100) anti-GBM antibody binding at OD 405 after the final immunization with antigen (ELISA)
c Control XenoMouse II animals, 2 immunized with PBS and 2 immunized with normal human IgG
d After the second immunization
Fig. 1. Proliferative glomerulonephritis in
XenoMouse II after immunization with
3(IV)NC1 collagen preparations. (A) Nor-
mal glomerulus from a non-immunized mouse
(400). (B) A glomerulus from a XenoMouse
II animal immunized with 3(IV)NC1 colla-
gen. Many glomeruli were enlarged, hypercel-
lular, and some had parietal epithelial activa-
tion (arrow; 400).
Fig. 2. Representative glomeruli from (A) Control XenoMouse II without IgG deposition (200), and (B) linear IgG deposits in XenoMouse II
along the GBM and (C) TBM of a XenoMouse II animal, following immunization with 3 (IV) NC1 (400).
of the 3(IV)NC1 collagen proteins (Table 1). By con- deposits along the GBM with variable and weaker TBM
staining (Fig. 2). Murine C3 was present also, althoughtrast neither unimmunized XenoMouse II animals nor
XenoMouse II animals immunized with human IgG or the intensity of staining varied from 1 to 2. Naı¨ve and
control XenoMouse II animals had negative staining for1(IV)NC1 collagen had detectable anti-3 antibody ac-
tivity at any time (P	 0.001). All of the mice immunized C3. Light microscopic evaluation of the lungs showed
patchy alveolar hemorrhage in some animals (data notwith 3(IV)NC1 developed proteinuria, elevated serum
creatinine levels and histologic evidence of nephritis. shown).
Proteinuria was present following immunization with
A fully human anti-GBM 3(IV)NC1 autoantibodyeach of the 3(IV)NC1 collagen preparations, and the
shares structural determinants with human serummean value three weeks after initial immunization varied
autoantibodies and transfers disease to naı¨veto some extent with the immunogen (Table 1). The mean
XenoMouse IIserum creatinine concentrations increased in all Xeno-
Mouse II animals immunized with 3(IV)NC1 collagen A monoclonal anti-3(IV)NCl antibody (mAb F1.1)
derived from a XenoMouse II animal immunized with(Table 1).
Furthermore, all of the 3(IV)NC1 immunized Xeno- bovine NCl collagen was selected for further evaluation.
This human monoclonal Ig2 Ab did not express eitherMouse II animals developed proliferative glomerulone-
phritis (Fig. 1). By direct immunofluorescence all of the murine heavy or light chains [confirming that the anti-
3(IV)NC1 collagen mAb was fully human; data not3(IV)NC1 immunized XenoMouse II had linear IgG
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Fig. 3. Binding of human monoclonal anti-
body (mAb) F.1.1 to 3(IV)NC1. (A) Human
mAb F.1.1 binds to both recombinant and na-
tive (bovine) 3(IV)NC1 derived proteins.
Symbols are: ( ) E. coli expressed recombinant
3(IV)NC1 antigen; () collagen (IV)NC1
bovine dimers. Binding of serum from a pa-
tient with Goodpasture’s disease (GPS), nor-
mal human serum and an irrelevant human
mAb is shown (direct binding, ELISA).
Monoclonal Ab F1.1 does not bind 1(IV)
NC1 collagen. (B and C) Monoclonal Ab F1.1
binds both human fetal kidney cell and E. coli
expressed recombinant antigens. (B) Direct
binding of F1.1 to E. coli and 293 cell-derived
antigens (ELISA). Symbols are: () series 1,
200 ng/well of E. coli expressed r3(IV)NC1;
() series 2, 200 ng/well of 293 mammalian cell
expressed r3(IV)NC1. (C) Western blotting
demonstrating mAb F1.1 (lanes 1 and 5), af-
finity purified Goodpasture’s serum Ab (lanes
2 and 6) and normal human IgG (lanes 3 and
4) to 293 and E. coli expressed antigens. Lanes
1 to 3 are 293 cell expressed antigen 5000 ng/
lane; Lanes 4 to 6 are E. coli cell expressed
antigen 3000 ng/lane.
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the range of inhibition found with purified anti-GBM
patient sera [19]. MAb F1.1 also binds in a linear fashion
to normal human kidney by direct IF; for comparison
the binding of affinity purified polyclonal human anti-
GBM autoantibodies, derived from a patient with active
disease, is shown (Fig. 5).
After IV administration of purified monoclonal or
polyclonal Ab into XenoMouse II, the animals devel-
oped proteinuria (Table 2), and a mild proliferative ne-
phritis that was associated with human IgG deposition.
The direct IF staining was similar to the deposition ob-
served after administration of polyclonal, affinity puri-
fied human anti-3(IV)NC1 collagen Ab to XenoMouse
II (not shown). No proteinuria, nephritis or IF staining
was noted after normal human IgG administration.
DISCUSSION
Fig. 4. Human mAb F1.1 expresses Id-GBM. Competitive ELISA for Induction of anti-GBM disease in XenoMouse II rep-
Id-GBM activity demonstrate the inhibitory activity of F1.1. Maximum resents the first description of actively induced disease ininhibition is comparable to that obtained with affinity purified, human
a mouse mediated by human autoantibodies. Followingpolyclonal anti-3(IV) Ab derived from patient’s sera [19] as illustrated
by the mean inhibition (
1 SD) on the left side of the Figure. For administration of 3(IV) collagen XenoMouse II ani-
comparison, inhibition by an irrelevant human mAb also is illustrated mals produce human anti-3(IV) collagen antibodies(top curve).
that deposited in a linear manner along the glomerular
basement membrane. This initiated proliferative glomer-
ulonephritis, as manifest by histologic changes, protein-
shown]. It was necessary to determine this, as there can uria and elevated serum creatinine concentrations [3,
sometimes be a leak of mouse lambda light chain [17]. 22, 23].
Monoclonal Ab F1.1 bound bovine 3(IV)NC1 collagen, The relevance of the XenoMouse II animal model to
E. coli (prokaryote) and 293 cell (eukaryote) expressed the spontaneous human form of the disease is further
antigens as determined by ELISA (Fig. 3 A, B). Mono- supported by both the antigenic specificity of the autoan-
clonal Ab F1.1 did not bind to 293 human expressed tibody response and shared idiotypic properties of the
1(IV)NC1 collagen. Monoclonal Ab F1.1 bound E. coli serum autoantibody populations in XenoMouse II ani-
(prokaryote) and 293 cell (eukaryote) expressed anti- mals and patients with the disease [10, 19]. The shared
gens as determined by Western blotting (Fig. 3C), al- idiotype was present between both the serum antibodies
though the mAb appeared to bind more strongly to the in XenoMouse II animals and a pathogenic monoclonal
E. coli expressed antigen than to the 293-cell expressed antibody. Taken together, the results support structural
antigen (by Western blotting). Polyclonal human and relatedness among the antibody populations and they
XenoMouse II anti-GBM serum, and MAb F1.1 bound raise the possibility that similar genes are used to encode
to non-reduced 293 human expressed 3(IV)NC1 colla- them. Studies are currently underway to address this
gen and to a variable but lesser extent to mercaptopu- possibility.
rine-reduced antigen by Western blotting (data not Of particular interest, all of the 3(IV) preparations
shown). used in these studies elicited an autoimmune and patho-
genic response. The results confirm previous observa-
A human monoclonal anti-GBM antibody shares tions that these different preparations are capable of
antigenic and structural properties with patient inducing a pathogenic response in mice. Nevertheless,
serum anti-GBM autoantibodies and transfers the XenoMouse II animals immunized with correctly
disease to XenoMouse II folded antigen (that is, mammalian cell derived) ap-
peared to produce a more severe pathologic response.Monoclonal antibody F1.1 also shares idiotypes with
anti-GBM antibodies derived from patients with active This finding is consistent with recent reports that proper
folding of 3(IV), determined by NC1 domain residuesdisease (Fig. 4). In previous experiments we observed
that all patients with anti-3(IV)NC1 collagen Ab ex- 17-31 (EA) and 127-141 (EB) of 3(IV) collagen, is
required for control of the disulfide bond-dependentpressed this idiotypically defined structural determinant
[19]. As shown on the left side of the figure, the inhibition conformational epitopes for binding of human serum
autoantibodies [20]. Further evaluation of mice at differ-(that is, idiotype activity) by mAb F1.1 (50%) is within
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Fig. 5. Human mAb F1.1 and affinity purified
human anti-GBM antibodies bind to normal
human kidney as shown by indirect immuno-
fluorescence (IF), as labeled. Data are in the
Methods section. (A) Negative control human
monoclonal antibody. (B) Monoclonal anti-
body F1.1 supernatant. (C) Monoclonal anti-
body F1.1 purified concentrate. (D) Negative
control human polyclonal serum. (E) Human
anti-GBM polyclonal antibodies.
Table 2. Passive administration of human anti-3(IV)NC1 mAb (F1.1)
Antigen (N mice) Urine proteina mg/24 h Creatininea mg/dL LM Direct IF
Controls (4) 	1.0 0.07
0.03 Normal, no proliferation No staining
Monoclonal F1.1 (4) 2.4 0.7 Proliferative GN 2 Punctate 2
Polyclonal anti-GBM Ab (4) 1.6 0.8 Patchy mesangial expansion Punctate 2
a Average urine protein and serum creatinine concentrations five days after passive antibody administration
ent stages of disease along with pathogenic evaluation of taining to the origins of this subset of pathogenic human
human mAb with varying properties should help address autoantibodies and further insights into the structural
this issue. basis of pathogenic autoantibody binding. If successful,
The results of previous attempts to induce anti-GBM this approach should lead to design of reagents that spe-
disease in mice, including nephritis and pulmonary hem- cifically target pathogenic autoantibodies and the B cells
orrhage, have been variable and dependent on multiple that express them. Once derived, the efficacy of these
factors, including autoantibody production and T cell- agents could then be directly tested in this new model,
mediated events. The influence of Class II genes is sup- prior to evaluation in patients with disease.
ported by the observation that disease is more severe in
SJL mice (H-2s) than in AJ mice (H-2k) [15, 24, 25]. In
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